Frequency and risk factors of ulcerative colitis associated colorectal cancer referral center experience in non-endemic area

Abstract

Aims: The incidence of colorectal cancer (CRC) in ulcerative colitis (UC) patients varies across different geographical regions, with limited data available from non-endemic areas for sporadic CRC. This study aimed to evaluate the CRC rates and risk factors in UC patients in a non-endemic region for sporadic CRC. Methods: A retrospective cohort study was conducted on UC patients who had at least 6 months of follow-up between June 1993 and February 2023 at a tertiary referral center in Turkey. Risk factors for CRC development were assessed, including age at UC onset, disease duration, extent of colitis, family history of CRC, and treatment response. Results: A total of 875 UC patients were included in the study. The median age at diagnosis was 38 years, and the median follow up period was 8.16 years. Of these patients, 133 (15.2%) had proctitis, 426 (48.7%) had left-sided colitis, and 316 (36.1%) had extensive colitis. CRC was histologically diagnosed in 5 (0.6%) UC patients, with a median UC onset age of 29.4 years and a total disease duration of 18 years. The median age at CRC diagnosis was 46 years. Three patients had extensive colitis, while two had left-sided colitis. Three patients had steroid dependence, two had thiopurine resistance, and one was biologic treatment resistant. All UC-related CRC patients had persistent mild to moderate disease activity on colonoscopy during follow-up. Conclusion: The low incidence of UC-associated CRC in non-endemic areas may be associated with some environmental and racial factors specific to the region.

Keywords

• Colorectal cancer
• ulcerative colitis
• non-endemic area

References

1. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113
2. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738-745. doi:10.1053/j.gastro.2009.12.037
3. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-645. doi:10.1016/j.cgh.2012.01.010
4. Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a cochrane systematic review and meta-analysis. Am J Gastroenterol. 2018;113(12):1801-1809. doi:10.1038/s41395-018-0354-7
5. Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol. 2017;14(4):218-229. doi: 10.1038/nrgastro.2017.1
6. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14(25):3937-3947. doi:10.3748/wjg.14.3937
7. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18(29):3839-3848. doi:10.3748/wjg.v18.i29.3839
8. Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022;128(24): 4251-4284. doi:10.1002/cncr.34479

9. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
10. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18): 1228-1233. doi:10.1056/NEJM199011013231802
11. Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. 2020; 395(10218):123-131. doi:10.1016/S0140-6736(19)32545-0
12. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(3):133-140. doi:10.1055/s-2005-916274
13. Keller DS, Windsor A, Cohen R, Chand M. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3-13. doi:10.1007/s10151-019-1926-2
14. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14(2):89-103. doi:10.5114/pg.2018.81072
15. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004; 126(6):1634-1648. doi:10.1053/j.gastro.2004.03.025
16. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345(2):235-241. doi:10.1016/j.canlet.2013.07.032
17. O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(8):1411-1420. doi:10.1002/ibd.21217
18. de Campos Silva EF, Baima JP, de Barros JR, et al. Risk factors for ulcerative colitis-associated colorectal cancer: a retrospective cohort study. Medicine (Baltimore). 2020;99(32):e21686. doi:10.1097/MD. 0000000000021686
19. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
20. Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945-965. doi:10.1093/ecco-jcc/jjv141
21. Han YD, Al Bandar MH, Dulskas A, et al. Prognosis of ulcerative colitis colorectal cancer vs. sporadic colorectal cancer: propensity score matching analysis. BMC Surg. 2017;17(1):28. doi:10.1186/s12893-017-0224-z
22. Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10(10):1224-1236. doi:10.1093/ecco-jcc/jjw054
23. Mañosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47(5):605-614. doi:10.1111/apt.14494
24. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-535. doi:10.1136/gut.48.4.526
25. Kekilli M, Dagli U, Kalkan IH, et al. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. Scand J Gastroenterol. 2010;45(4):434-439. doi:10. 3109/00365520903540830
26. Ünal NG, Özütemiz Ö, Tekin F, Turan İ, Osmanoğlu N. Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turk J Gastroenterol. 2019;30(2):139-147. doi: 10.5152/tjg.2018.18221
27. Everhov ÅH, Erichsen R, Järås J, et al. Colorectal cancer in elderly-onset inflammatory bowel disease: a 1969-2017 Scandinavian register-based cohort study. Aliment Pharmacol Ther. 2022;56(7):1168-1182. doi:10. 1111/apt.17175
28. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854-862. doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
29. Tozun N, Atug O, Imeryuz N, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol. 2009;43(1):51-57. doi:10.1097/MCG. 0b013e3181574636